5 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Mirati (MRTX) Gets EU Nod for Krazati in KRAS-Mutated NSCLC https://www.zacks.com/stock/news/2208792/mirati-mrtx-gets-eu-nod-for-krazati-in-kras-mutated-nsclc?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2208792 Jan 11, 2024 - Mirati's (MRTX) Krazati gets the European Commission's conditional marketing approval for treating adult patients with KRASG12C-mutated advanced non-small cell lung cancer.
FDA Rejects Amgen's (AMGN) NDA Seeking Full Nod for Lumakras https://www.zacks.com/stock/news/2202718/fda-rejects-amgen-s-amgn-nda-seeking-full-nod-for-lumakras?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202718 Dec 27, 2023 - Per the FDA, Amgen (AMGN) will need to complete an additional confirmatory study on Lumakras in certain lung cancer patients before February 2028 to secure full approval.
Bristol Myers (BMY) to Buy Cancer Drug-Maker RayzeBio for $4.1B https://www.zacks.com/stock/news/2202691/bristol-myers-bmy-to-buy-cancer-drug-maker-rayzebio-for-4-1b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2202691 Dec 27, 2023 - Bristol Myers (BMY) is set to acquire RayzeBio for $4.1 billion to strengthen and diversify its already established oncology portfolio. The transaction is expected to close in the first half of 2024.
Bristol Myers (BMY) to Buy Karuna Therapeutics for $14B https://www.zacks.com/stock/news/2201667/bristol-myers-bmy-to-buy-karuna-therapeutics-for-14b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201667 Dec 22, 2023 - Bristol Myers (BMY) announces a second acquisition in two months. It is set to buy Karuna Therapeutics, Inc. (KRTX) for $14 billion to strengthen its neuroscience portfolio.
Bristol Myers (BMY) Partners With SystImmune for Oncology Drug https://www.zacks.com/stock/news/2196867/bristol-myers-bmy-partners-with-systimmune-for-oncology-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196867 Dec 12, 2023 - Bristol Myers (BMY) is set to co-develop and co-commercialize oncology candidate BL-B01D1 in the United States with SystImmune.

Pages: 1

Page 1